anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hypoxia and oxidative stress contribute to the development of pulmonary hypertension (PH). tRNA-derived fragments play important roles in RNA interference and cell proliferation, but their epitranscriptional roles in PH development have not been investigated. We aimed to gain insight into the mechanistic contribution of oxidative stress-induced 8-oxoguanine in pulmonary vascular remodeling.
METHODS: Through small RNA modification array analysis and quantitative polymerase chain reaction, a significant upregulation of the 8-oxoguanine -modified tRF-1-AspGTC was found in the lung tissues and the serum of patients with PH.
RESULTS: This modification occurs at the position 5 of the tRF-1-AspGTC (5o8G tRF). Inhibition of the 5o8G tRF reversed hypoxia-induced proliferation and apoptosis resistance in pulmonary artery smooth muscle cells. Further investigation unveiled that the 5o8G tRF retargeted mRNA of WNT5A (Wingless-type MMTV integration site family, member 5A) and CASP3 (Caspase3) and inhibited their expression. Ultimately, BMPR2 (Bone morphogenetic protein receptor 2) -reactive oxygen species/5o8G tRF/WNT5A signaling pathway exacerbated the progression of PH.
CONCLUSIONS: Our study highlights the role of site-specific 8-oxoguanine-modified tRF in promoting the development of PH. Our findings present a promising therapeutic avenue for managing PH and propose 5o8G tRF as a potential innovative marker for diagnosing this disease.
Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
An angle bracket constructed from a single piece metal blank. The bracket is of a substantially triangular shape. In one embodiment of the invention the bracket has a U-shaped cross-section providing added stability. A method is disclosed for constructing the bracket from the metal blank. The method includes the steps of folding the metal blank along preformed fold lines to form its triangular shape. The method also includes the steps of folding the metal blank along additional preformed fold lines to form its U-shaped cross-section.
FIELD: medicine, otolaryngology. SUBSTANCE: invention relates to method of treatment of patients with inflammatory diseases in upper respiratory tracts. Method involves administration of capsule polysaccharide of antigen of Haemophilus influenzae of type b by intranasal route, six times, once per three days in the dose 0.2 ml as measured 1 mg/ml. This method ensures to prevent the development of inflammatory process in upper respiratory tracts and possibility of complications arising. EFFECT: improved method of prophylaxis. 2 ex
Colorectal cancer (CRC) stands as the second most common cause of cancer-related mortality globally and p53, a widely recognized tumor suppressor, contributes to the development of CRC. Ubiquitin-specific protease 36 (USP36), belonging to the deubiquitinating enzyme family, is involved in tumor progression across multiple cancers. However, the underlying molecular mechanism in which USP36 regulates p53 signaling pathway in CRC is unclear. Here, our study revealed that USP36 was increased in CRC tissues and associated with unfavorable prognosis. Functionally, elevated USP36 could promote proliferation, migration, and invasion of CRC cells in vitro and in vivo. Mechanistically, USP36 could interact with and stabilize RBM28 via deubiquitination at K162 residue. Further, upregulated RBM28 could bind with p53 to suppress its transcriptional activity and therefore inactivate p53 signaling pathway. Collectively, our investigation identified the novel USP36/RBM28/p53 axis and its involvement in promoting cell proliferation and metastasis in CRC, which presents a promising therapeutic strategy for CRC treatment.
MTX is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
In the DOT Diary research project, the AiCure automated directly observed therapy (aDOT) smartphone app has been adapted for use in monitoring and supporting HIV pre-exposure prophylaxis (PrEP) use among young men who have sex with men (YMSM). The aDOT app uses automated directly observed therapy (DOT) that use the smartphone camera and artificial intelligence software to confirm that the right person is taking the right medication at the right time. A sexual diary has been integrated into the aDOT app to assist YMSM in understanding whether they are receiving protection from PrEP for individual sexual episodes, and when it is particularly important to take PrEP (e.g. after a sexual episode). Specifically, the sexual diary allows participants to track sexual encounters, sexual behaviors that occurred in each encounter, and rating characteristics of partners. The app provides a calendar displaying all days in which PrEP medication was taken, and all days in which sexual activity occurred, allowing participants to see coverage of sexual encounters with PrEP. Based on pharmacokinetic and pharmacodynamic data from prior PrEP trials, the app will also indicate the estimated level of protection achieved from PrEP (e.g. low, medium, high), and also provide personalized messages on the additional numbers of doses needed to maximize protection.

In the next stage of app development and assessment, the researchers will conduct the DOT Diary Longitudinal Pilot to assess the impact of the app on PrEP adherence as measured by pharmacokinetic measures of PrEP use (tenofovir diphosphate \[TFV-DP\] and emtricitabine triphosphate \[FTC-TP\] levels in dried blood spots \[DBS\]). The researchers will also assess the concordance of TFV-DP and FTC-TP in DBS with adherence measured by DOT Diary, and the acceptability and ease of use of the app over a longer (24-week) period. This pilot study will allow evaluation and further refinement of the app in preparation for testing in a larger efficacy trial among YMSM at risk for HIV acquisition. The researchers will conduct this pilot protocol among YMSM in Atlanta and San Francisco Bay Area, two metropolitan regions heavily impacted by HIV, yet differing in sociodemographics, as well as in the availability and uptake of HIV prevention services, including PrEP. These diverse research locations will allow collection of data to inform app development among a broad group of YMSM.
The present invention provides an Antibody Drug Conjugate (ADC) or a pharmaceutically acceptable salt thereof. The ADC comprises a tetravalent monoclonal antibody coupled to a cytotoxic drug via a chemical linker. The monoclonal antibody comprises two long chains and four short chains. Monoclonal antibodies include two long chains and four short chains. Each of the longchains includes a first segment located near the N-terminus of the longchain and a second segment located near the C-terminus of the longchain. Each of said first fragments and each of said second fragments are paired with one of said short chains, thereby forming antigen-binding fragment domains, and thus four antigen-binding fragment domains, specific for the same antigen. The invention also provides pharmaceutical compositions comprising the ADCs and methods of using the compositions in the treatment of disease.
Vaccination is the most effective means of preventing and controlling porcine epidemic diarrhea (PED). Conventional vaccines developed from porcine epidemic diarrhea virus (PEDV) GI-a subtypes (CV777 and SM98) have played a vital role in preventing classical PED. However, with the emergence of PEDV mutants in 2010, conventional PEDV GI-a subtype-targeting vaccines no longer provide adequate protection against PEDV GII mutants, thereby making novel-type PED vaccine development an urgent concern to be addressed. Novel vaccines, including nucleic acid vaccines, genetically engineered subunit vaccines, and live vector vaccines, are associated with several advantages, such as high safety and stability, clear targeting, high yield, low cost, and convenient usage. These vaccines can be combined with corresponding ELISA kits to differentiate infected from vaccinated animals, which is beneficial for disease confirmation. This review provides a detailed overview of the recent advancements in PED vaccines, emphasizing on the research and application evaluation of novel PED vaccines. It also considers the future directions and challenges in advancing these vaccines to widespread use in clinics.
PURPOSE: To obtain the subject agent having effective drug action and excellent in safety by compounding 1,2-dihydro-7,8,9-trihydroxycyclopenta[C] [2]benzopyran-3,5-dione. CONSTITUTION: This agent is obtained by compounding a compound of the formula as an active component with a conventional vehicle (e.g. starch), binder (e.g. hydroxypropyl cellulose), lubricant (e.g. magnesium stearate), disintegrating agent, stabilizer, humectant, surfactant, etc., and the resultant mixture is formulated in a common manner. The agent can be prepared in a form of tablets, granules, capsules, an injection, an infusion solution, etc. The daily dose for an adult is 1-100mg, which is administered in 1-3 divided doses. Having low toxicity, the agent can be administered continuously in large amounts and can demonstrate excellent effect.
BACKGROUND: Sarcopenia negatively affects the short-term prognosis of hospitalized older adults. However, no evidence currently supports a direct relationship between sarcopenia and readmission among individuals who have experienced an acute stroke. Therefore, we investigated whether sarcopenia is associated with readmission after discharge.
METHODS: This retrospective cohort study included patients who had experienced acute stroke. Sarcopenia was defined as the coexistence of low skeletal muscle mass index (SMI) and grip strength. We applied the log-rank test and Cox proportional hazards regression analysis to analyze whether sarcopenia, low SMI, and low grip strength were associated with readmission within 6 months.
RESULTS: Among 228 included patients (mean age, 72.8 years; 146 males), the prevalence of sarcopenia was 24.6% (n=56; male 17.8%; female 36.6%). Cox proportional hazards regression analysis using the propensity score as a covariate revealed that sarcopenia (hazard ratio [HR]=7.21; 95% confidence interval [CI] 1.45-35.8; p=0.016) and low skeletal muscle mass (HR=7.40; 95% CI 1.14-48.1; p=0.036), but not low grip strength (HR=1.42; 95% CI 0.281-7.21; p=0.670), were significantly associated with readmission for stroke within 6 months.
CONCLUSIONS: Sarcopenia was negatively associated with readmission within 6 months of stroke onset in patients in Japan who had experienced an acute stroke. These findings suggest that the identification of sarcopenia may facilitate prognostic prediction from the acute stage and intervention(s) to prevent rehospitalization.
BACKGROUND: The natural history and pathophysiology of diverticular disease (DD) are still uncertain. An ex-vivo human complicated DD (cDD) model has recently shown a predominant transmural oxidative imbalance. The present study aims to evaluate whether the previously described alterations may precede the symptomatic form of the disease.
METHODS: Colonic surgical samples obtained from patients with asymptomatic diverticulosis (DIV), complicated DD, and controls were systematically and detailed morphologically and molecularly analyzed. Therefore, histologic, histomorphometric, immunohistochemical evaluation, and gene and protein expression analysis were performed to characterize colonic muscle changes and evaluate chronic inflammation, oxidative imbalance, and hypoxia. Functional muscle activity was tested on strips and isolated cells in response to contractile and relaxant agents.
KEY RESULTS: Compared with controls, DD showed a marketed increase in muscle layer thickness, smooth muscle cell syncytium disarray, and increased interstitial fibrosis; moreover, the observed features were more evident in the cDD group. These changes mainly affected longitudinal muscle and were associated with altered contraction-relaxation dynamics and fibrogenic switch of smooth muscle cells. Chronic lymphoplasmacytic inflammation was primarily evident in the mucosa and spared the muscle. A transmural increase in carbonylated and nitrated proteins, with loss of antioxidant molecules, characterized both stages of DD, suggesting early oxidative stress probably triggered by recurrent ischemic events, more pronounced in cDD, where HIF-1 was detected in both muscle and mucosa.
CONCLUSION & INFERENCES: The different DD clinical scenarios are part of a progressive process, with oxidative imbalance representing a new target in the management of DD.
Subjects assigned to the experimental group will take approximately 20 mg/kg/day of placebo (corn starch) for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration. Placebo treatment begins at 8 weeks after surgery.
Absorption: Ipratropium bromide is poorly absorbed into the systemic circulation following oral administration (2-3%). Less than 20% of an 84 mcg per nostril dose was absorbed from the nasal mucosa of normal volunteers, induced-cold patients, or perennial rhinitis patients.

Distribution: Ipratropium bromide is minimally bound (0 to 9% in vitro) to plasma albumin and α1-acid glycoprotein. Its blood/plasma concentration ratio was estimated to be about 0.89. Studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier.

Metabolism: Ipratropium bromide is partially metabolized to ester hydrolysis products, tropic acid and tropane. These metabolites appear to be inactive based on in vitro receptor affinity studies using rat brain tissue homogenates.

Elimination: After intravenous administration of 2 mg ipratropium bromide to 10 healthy volunteers, the terminal half-life of ipratropium was approximately 1.6 hours. The total body clearance and renal clearance were estimated to be 2,505 and 1,019 mL/min, respectively. The amount of the total dose excreted unchanged in the urine (Ae) within 24 hours was approximately one-half of the administered dose.

Pediatrics: Following administration of 42 mcg of ipratropium bromide per nostril two or three times a day in perennial rhinitis patients 6-18 years old, the mean amounts of the total dose excreted unchanged in the urine (8.6 to 11.1%) were higher than those reported in adult volunteers or adult perennial rhinitis patients (3.7 to 5.6%). Plasma ipratropium concentrations were relatively low (ranging from undetectable up to 0.49 ng/mL). No correlation of the amount of the total dose excreted unchanged in the urine (Ae) with age or gender was observed in the pediatric population.

Special Populations: Gender does not appear to influence the absorption or excretion of nasally administered ipratropium bromide. The pharmacokinetics of ipratropium bromide have not been studied in patients with hepatic or renal insufficiency or in the elderly.

Drug-Drug Interactions: No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions.
The records will be obtained at the first visit, which will be one week before placing brackets. At the second visit, the orthodontic appliances will be applied; then assessments will be taken after 15 minutes of showing the patient the digital simulation of their teeth alignment at the end of orthodontic treatment.
PURPOSE:To prevent degrading in a medical liquid by a method wherein pollutants of an outer cylinder, a top cap mounted on a nozzle part thereof and a gasket mounted on an opening of the outer cylinder are removed and sterilized, silicone oil sterilized is applied on the internal wall of the outer cylinder and the outer cylinder is filled with a medical liquid cleared of microorganisms and foreign matters in an axemic manner. CONSTITUTION:An outer cylinder 1, a top cap 4 with a nozzle 2 sealed and a gasket 5 mounted an open end 3 of the outer cylinder on the side opposite to the nozzle 2 is cleaned up by an air cleaning to remove foreign matters and pollutants. Then, a sterilization treatment is performed by an autoclave sterilization or the like. A medical liquid is used to remove the microorganisms and the foreign matters by an axemic filtration method. In this case, multi-stage filtration is preferable. Silicone oil sterilized is applied on the internal of the outer cylinder 1 sterilized in an axemic manner and the top cap 4 sterilized is mounted on the nozzle 2 to fill the medical liquid sterilized at the open end 3 in an exemic manner. Then, the gasket 5 sterilized is mounted on the open end 3.
This disclosure provides techniques of synchronizing the playback of two recorded videos of the same surgical procedure. In one aspect, a process for generating a composite video from two recorded videos of a surgical procedure is disclosed. This process begins by receiving a first and second surgical videos of the same surgical procedure. The process then performs phase segmentation on each of the first and second surgical videos to segment the first and second surgical videos into a first set of video segments and a second set of video segments, respectively, corresponding to a sequence of predefined phases. Next, the process time-aligns each video segment of a given predefined phase in the first video with a corresponding video segment of the given predefined phase in the second video. The process next displays the time-aligned first and second surgical videos for comparative viewing.
The present invention relates to a recording medium which minimizes a laterality error in a hospital information system (HIS) and a use thereof. The recording medium according to the present invention comprises an input module and a correction module, and includes an algorithm for detecting and correcting a laterality error between the recording medium and patient information in real time, in a hospital information system. For actual implementation, the detection and the correction of a laterality error between a medical examination name and a medical report using a macro program has been identified in a radiologic report. Using the recording medium of the present invention, all of laterality errors (discrepancy between the medical examination name and the medical report) not more than 0.05%, which actually existed in a hospital information system, could be detected and corrected. Further, using the recording medium in the future, it would be possible to prevent possible occurance of the laterality error. Thus, the recording medium of the present invention and a system using the same can remarkably reduce the laterality error in the hospital information system, thereby providing a more accurate medical service to a patient. Moreover, the recording medium and the system can more actively take action against issues in accurate medicine and patient protection, which are recently spotlighted, and thus can effectively induce increase in productivity and competitiveness of a medical service in a hospital (e.g. increase in productivity and improvement of a medical service through medical treatment and medical treatment support).
Sacituzumab govitecan (10 mg/kg) administered intravenously on Days 1 and 8 of a 21-day cycle. Patients will be treated until progression, death, study withdrawal, or unacceptable toxicity.
FIELD: chemistry of physiologically active compounds. SUBSTANCE: proposed compound shows low toxicity (A 2 ) that 2.2 fold less as compared with that for remantadin and shows also antiviral activity. Its antiviral activity against influenza virus LD 50 = 441 mg/kg Victoria exceeds that of remantadin by 1.4 fold. Compound can be used as prophylaxis antiviral agent in pharmacology and medicine. EFFECT: enhanced effectiveness of agent proposed. 2 tbl
PURPOSE:To obtain an antiviral agent having anti-HIV action, comprising a component containing Euphorbia Kansui Liou as an active ingredient. CONSTITUTION:This antiviral agent contains an extract of Euphorbia Kansui Liou, a fleshy perennial plant or a component squeezed from the plant as an active ingredient. The extraction is carried out by using water or an organic solvent (e.g. ethanol), the prepared extract or squeezed component is directly used as the antiviral agent as it is, or water or the solvent is distilled away under reduced pressure and the extract is concentrated and used, or the extract or the concentrate is dried and used as powder. A diterpene derivative of formula I or II (R1 to R7 each is H, a 1-20C acyl, benzoyl or a 1-5C alkyl; X is carbonyl or CH(OH); R8-R12 are each H, OH, a 1-20C acyloxy, a 1-5C alkoxy, etc.) derived from Euphorbia Kansui Liou or a terpene prepared from Euphorbia Kansui radix is used as an active ingredient to give the objective antiviral agent. The daily dose is about 0.01-500mg/kg.
BACKGROUND: Arteriovenous Fistula (AVF) surveillance is required to detect early dysfunction (thrombosis, stenosis) and its timely correction prolongs access-patency. Clinical examination (CE) and doppler have been used as screening/surveillance of AVF, for early detection of AVF dysfunction. Since there was inadequate evidence for KDOQI to make recommendations on AVF surveillance and on secondary failure rate. We compared CE, doppler and fistulogram as surveillance modalities in detecting a secondary failure in matured AVF.
METHODOLOGY: This prospective-observational, single-center study, was done between December 2019-April 2021. CKD stage 5 patients on dialysis/Not-on-dialysis with matured AVF were included at third month. CE, doppler (blood flow, vein diameter, depth), and fistulogram were done at third and sixth month. Secondary failure was assessed at sixth month classifying AVF to patent/functional and failed group. Diagnostic tests were performed by comparing three methods considering fistulogram as gold-standard. Residual urine output is also monitored to look for any contrast induced residual renal function loss.
RESULTS: Of total 407 created AVF, 98 (24%) had primary failure. Twenty-five (6%) had surgical complications including unsuccessful AVF and aneurysm/rupture, 156 lost follow-up at third month, 104 consented patients were enrolled, 16 lost to follow-up subsequently, and 88 patients' data were analyzed at the end. At the sixth month, 76(86.4%) had patent AVF, 8 (9.1%) had secondary failure (Thrombosis-4, Central Venous Stenosis-4), and 4 (4.1%) patients expired. Considering fistulogram as a diagnostic standard, CE showed 87.5% sensitivity, and 93.4% specificity (cohen's kappa value of 0.66). Doppler had sensitivity and specificity of 87% and 96% respectively (cohen's kappa value of 0.75), Combination of clinical examination with doppler showed sensitivity and specificity of 100% and 89% respectively.
CONCLUSION: Although the secondary AVF failure rate is less than the primary, CE is an important and valuable tool in the diagnosis and surveillance of AVF in detecting its dysfunction. Moreover, CE with doppler can be used as a surveillance protocol that can detect early AVF dysfunction at par with Fistulogram.